Hyderabad, March 25, 2025: HRV Global Life Sciences, a leading provider of innovative solutions for the pharmaceutical and life sciences industry, participated in DCAT Week 2025, the premier event for the global bio/pharmaceutical manufacturing value chain. Held in New York, the event brought together industry leaders, innovators, and decision-makers from around the world to discuss emerging trends, forge strategic partnerships, and drive advancements in pharmaceutical development and manufacturing.
Attending DCAT Week 2025 provided HRV Global Life Sciences’ with a valuable platform to explore new business opportunities and forge new partnerships with US industry influencers. As one of the leaders in the virtual pharma segment, the company is setting new benchmarks in the industry through its innovative approach to pharmaceutical manufacturing and distribution. The company has a pipeline of over 25 products to be launched in US and European markets in the current year.
India’s pharmaceutical industry, valued at around USD 55 billion, is expected to grow 2.2 to 2.4 times over the next six years, reaching USD 120 billion to USD 130 billion by 2030. HRV Global Life Sciences is well-positioned to drive India’s transition from a volume-based exporter to a leader in high-value products, reinforcing its position in the global pharmaceutical market.
Speaking on the participation, Mr. Hari Kiran Chereddi, Managing Director of HRV Global Life Sciences, said, “DCAT Week 2025 provided an incredible platform for HRV Global Life Sciences to connect with industry leaders, exchange valuable insights, and strengthen our global partnerships. We had productive discussions on the evolving needs of the industry. We identified new opportunities for collaboration that will help drive innovation, facilitate global market expansion, and reinforce India’s position as a key player in the international pharmaceutical landscape.”
With India’s pharmaceutical sector driving the country’s economic growth, HRV Global Life Sciences is well-positioned to capitalise on this momentum. Its strong global network and focus on innovation enable the company to support this growth and meet the evolving needs of the pharmaceutical industry.
Corporate Comm India (CCI Newswire)
